

Special Issue

The Interplay of Gut Dysbiosis with Metabolic Syndrome

Message from the Guest Editor

Dysbiosis of the gut microbiota plays a crucial role in the pathogenesis of metabolic syndrome. Dysbiosis causes a cluster of interrelated physiological, biochemical, clinical, and metabolic risk factors that are associated with an increased likelihood of developing cardiovascular disease and type 2 diabetes. The main characteristics of metabolic syndrome are elevated blood pressure, dyslipidemia (defined as increased triglycerides and reduced high-density lipoprotein cholesterol), elevated fasting glucose, and central obesity. Manipulation of gut microbiota through the administration of prebiotics or probiotics could reduce intestinal low-grade inflammation and improve gut barrier integrity, thereby improving metabolic balance and promoting weight loss. However, additional evidence is required to fully comprehend their clinical impact and the therapeutic application of dysbiosis and its link with metabolic syndrome. We invite researchers working on the effects of gut dysbiosis on metabolic syndrome to submit original research articles or review papers for this Special Issue in order to advance our understanding of this complicated and intriguing topic.

Guest Editor

Dr. Shailendra Pratap Singh

New York Medical Research Scientist, New York Medical College, New York, NY, USA

Deadline for manuscript submissions

closed (31 January 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/145257

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).